Závodszky P, Vonderviszt F, Lakatos S, Kilár F, Simon I, Török J, Sziva D and Sárvári M (1985) Domain structure and signal transduction within antibody molecules.
In: Multidomain proteins (Eds: Patthy L and Friedrich P), pp. 157-174. Akadémiai Kiadó, Budapest
Vonderviszt F, Lakatos S, Gál P, Sárvári M, Závodszky P (1987) A molten globule-like unfolding intermediate of a four domains protein, the Fc fragment of the IgG molecule
Biochemical and Biophysical Research Communications 148: 92-98
Gál P, Sárvári M, Szilágyi K, Závodszky P and Schumaker V (1989) Expression of a hemolytically active human complement component C1r proenzyme in insect cells using a baculovirus vector
Complement and Inflammation 6: 433-441
Sárvári M, Csikós G, Sass M, Gál P, Schumaker V, Závodszky P (1990) Ecdysteroids increase the yield of recombinant protein produced in baculovirus insect cell expression system
Biochemical and Biophysical Research Communications 167: 1154-1161
Luo C, Thielens N, Gagnon P, Gál P, Sárvári M, Tseng Y, Tosi M, Závodszky P, Arlaud G and Schumaker V (1992) Recombinant human complement subcomponent C1s lacking beta-hydroxy-asparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex
Biochemistry 31: 4254-4261
Cseh S, Gál P, Sárvári M, Dobó J, Lőrincz Z, Schumaker V and Závodszky P (1996)
Functional effects of domain deletions in a multidomain serine protease, C1r
Molecular Immunology 33: 351-359
Sárvári M, Závodszky P, Molnár K, Lőw P and Sass M (1996) Baculovirus-mediated trans-epithelial transport of proteins in infected caterpillars
Journal of General Virology 78: 953-963
Sárvári M, Vágó I, Wéber C, Nagy J, Gál P, Mák M, Kósa J, Závodszky P, Pázmány T (2003) Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity
Journal of Neuroimmunology 137: 12-18
Urbányi Z, Forrai E, Sárvári M, Likó I, Illés J, Pázmány T (2005) Glycosaminoglycans inhibit
neurodegenerative effects of serum amyloid P component in vitro
Neurochemistry International 46: 471-477
Kurkó D, Boros A, Dezső P, Urbányi Z, Sárvári M, Nagy J, Szombathelyi Z, Szendrei G (2006) Flow cytometry-based method to analyse the change in tau phosphorylation in a hGSK-3beta and htau over-expressing EcR-293 cell line
Neurochemistry International 48: 374-382
10 Irodalmi hivatkozások
Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ (1996) Localization and cell association of C1q in Alzheimer’s disease brain. Experimental Neurology 138: 22-32
Agoropoulou C, Piddlesden SJ, Lachmann PJ, Wing MG (1998) Neuronal protection of oligodendrocytes from antibody-independent complement lysis. NeuroReport 9: 927-32
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WST, Hampel H, Hull M, Landreth G, Lue LF, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker DG, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer’s disease.
Neurobiology of Aging 21: 383-421
Beglopoulos V, Sun X, Saura C, Lemere CA, Kim RD, Shen J (2004) Reduced -amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. Journal of Biological Chemistry 279: 46907-14
Botto M, Dell’agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genetics 19: 56-9
Brachova L, Lue L, Schultz J, Rashidy TE, Rogers J (1993) Association cortex, cerebellum, and serum concentrations of C1q and Factor B in Alzheimer’s disease.
Molecular Brain Research 18: 329-34
Bradt B, Kolb WP, Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer’s disease -peptide. Journal of Experimental Medicine 188: 431-8
Brodsky-Doyle B, Leonard KR, Reid KBM (1976) CD and electronmicroscopy studies of human subcomponent C1q. Biocemical Journal 159: 279-86
Campbell RD, Law SK, Reid KB, Sim RB (1988) Structure, organization, and regulation of complement genes. Annual Reviews of Immunology 6: 161-95
Catterall CF, Lyons A, Sim RB, Day AJ, Harris TJ (1987) Characterization of the primary amino acid sequence of human complement control protein Factor I from an analysis of cDNA clones. Biochemical Journal 242: 849-56
Cseh S, Gál P, Sárvári M, Dobó J, Lőrincz Z, Schumaker N, Závodszky P (1996) Functional effects of domain deletions in multidomain serine protease, C1r.
Molecular Immunology 33: 351-9
Cummings JL (2004) Alzheimer’s disease. New England Journal of Medicine 351:56-67
Davis AE, Whitehead AS, Harrison RA, Dauphinais A, Bruns GA, Cicardi M, Rosen FS (1986) Human inhibitor of the first component of complement, C1: Characterization of cDNA clones and localization of the gene to chromosome 11.
Proceedings of National Academy of Sciences, USA 83: 3161-5
Eggleton P, Reid KB, Tenner AJ (1998) C1q – how many functions? How many receptors?
TRENDS in Cell Biology 8: 428-31
Eikelenboom P & Stam FC (1982) Immunoglobulins and complement factors in senile plaques. Acta Neuropathology 57: 239-42
Ember JA, Jagels MA, Hugli TE (1998) Characterization of complement anaphylatoxins and their biological responses. Human Complement System in Health and Disease (szerkesztők Frank MM & Volanakis J) Marcel Dekker, New York. 241-84. oldal
Erdei A (1990) C1q receptor on murine cells. Journal of Immunology 145: 1754-60
Esser AF (1994) The membrane attack complex of complement. Assembly, structure and cytotoxic activity. Toxicology 87: 229-47
Ezekovitz RA, Sim RB, Hill H, Gordon S (1984) Local opsonization by secreted macrophage complement components. Journal of Experimental Medicine 159: 244-60
Fonseca MI, Zhou J, Botto M, Tenner AJ (2004) Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer’s disease.
Journal of Neuroscience 24: 6457-65
Gaboriaud C, Thielens NM, Gregory LA, Rossi V, Fontecilla-Camps JC, Arlaud GJ (2004) Structure and activation of the C1 complex of complement.
TRENDS in Immunology 25: 368-73.
Gasque P, Fontaine M, Morgan BP (1995) Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. Journal of Immunology 154: 4726-33
Glenner GG & Wong CW (1984) Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein.
Biochemical Biophysical Research Communications 120: 885-90
Goate AM, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Guiffra L, Haynes A, Hardy JA (1991) Missense mutation int he amyloid precursor protein gene with Familial Alzheimer Disease. Nature 349: 704-6
Hsiao KK, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, A elevations, and amyloid plaques in transgenic mice.
Science 274: 99-102
Jenne D & Stanley KK (1985) Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO Journal 4: 3153-7
Jiang H, Robey FA, Gewurz H (1992) Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. Journal of Experimental Medicine 175: 1373-9
Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ (1994) B-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. Journal of Immunology 152: 5050-9
Johns TG & Bernard CC (1997) Binding of complement component C1q to myelin oligo-dendrocyte glycoprotein: A novel mechanism for regulating CNS inflammation.
Molecular Immunology 34: 33-8
Kirszbaum L, Sharpe JA, Murphy B, d’Appice AJ, Classon B, Hudson P, Walker ID (1989) Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems.
EMBO Journal 8: 711-8
Kristensen T & Tack BF (1986) Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proceedings of National Academy of Sciences, USA 83: 3963-7
Lassman H, Brück W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis patho-genesis: Implications for diagnosis and therapy.
TRENDS in Molecular Medicine 7: 115-21
Law SK & Levine RP (1977) Interaction between C3 and cell surface macromolecules. Proceedings of National Academy of Sciences, USA 74: 2701-5
Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Hsiao Ashe K, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. Journal of Neuroscience 20: 5709-14
Lublin DM, Liszewski MK, Post TW, Arce MA, Le Beau MM, Rebentisch MB (1988) Molecular cloning and chromosomal localization of human membrane cofactor protein: Evidence for inclusion in the multi-gene family of complement-regulatory proteins.
Journal of Experimental Medicine 168: 181-9
Luo C, Thielens N, Gagnon P, Gál P, Sárvári M, Tseng Y, Tosi M, Závodszky P, Arlaud G and Schumaker V (1992) Recombinant human complement subcomponent C1s lacking beta-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex. Biochemistry 31: 4254-62
Mackenzie IR & Munoz DG (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50: 986-90
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Proceedings of National Academy of Sciences, USA 82: 4245-9
Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O’Banion MK, Tenner AJ, Lemere CA, Duff K (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer’s disease.
American Journal of Pathology 158: 1345-54
McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989) Immune system response in Alzheimer disease. Canadian Journal of Neurological Sciences 16: 516-27
McGeer PL, McGeer E, Rogers J, Sibley J (1990) Anti-inflammatory drugs and Alzheimer disease. Lancet 335: 1037-9
McGeer PL & McGeer EG (1998) The importance of inflammatory mechanisms in Alzheimer disease. Experimental Gerontology 33: 371-8
Medof ME, Lublin DM, Holers M, Ayers DJ, Getty RR, Leykam JF, Atkinson JP, Tykocinski ML (1987) Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.
Proceedings of National Academy of Sciences, USA 84: 2007-11
Müller-Eberhard HJ, Dalmasso AP, Calcott MA (1966) The reaction mechanism of C3 i n immune hemolysis. Journal of Experimental Medicine 123: 33-49
Müller-Eberhard HJ (1988) Molecular organization and function of the complement system. Annual Review of Biochemistry 57: 321-47
Nagy J & László L (2002) Increased sensitivity to NMDA is involved in alcohol-withdrawal induced cytotoxicity observed in primary cultures of cortical neurons chronically pre-treated with ethanol. Neurochemistry International 40: 585-91
Olson JK & Miller SD (2004) Microglia initiates central nervous system innate and adaptive immune responses through multiple TLRs. Journal of Immunology 173: 3916-24
Pangburn MK & Müller-Eberhard HJ (1980) Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. Journal of Experimental Medicine 152: 1102-14
Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative complement pathway.
Journal of Experimental Medicine 154: 856-67
Piddlesden SJ & Morgan Morgan BP (1993) Killing of rat glial cells by complement: Deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. Journal of Neuroimmunology 48: 169-76
Podack ER, Tschopp J, Müller-Eberhard HJ (1982) Molecular organization of C9 within the membrane attack complex of complement.
Journal of Experimental Medicine 156: 268-82
Prechl J & Erdei A (2000) Immunomodulatory functions of murine CR1/2.
Immunopharmacology 49: 117-24
Reid KB & Porter RR (1976) Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochemical Journal 155: 19-23
Rent R, Myhrman R, Fiedel A, Gewurz H (1976) Potentiation of C1 esterase inhibitor activity by heparin. Clinical & Experimental Immunology 23: 264-71
Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I (1992) Complement activation by -amyloid in Alzheimer disease. Proceedings of National Academy of Sciences, USA 89: 10016-20
Roses AD (1996) Apolipoprotein E alleles as risk factors in Alzheimer disease.
Annual Reviews in Medicine 47: 387-400
Sárvári M, Csikós Gy, Sass M, Gál P, Schumaker VN, Závodszky P (1990) Ecdysteroids increase the yield of recombinant protein produced in baculovirus insect cell expression system. Biochemical and Biophysical Research Communications 167: 1154-61
Schifferli JA, Ng NC, Peters DK (1986) The role of complement and its receptor in the elimination of immune complexes. New England Journal of Medicine 315: 488-91
Schultz J, Schaller J, McKinley M, Bradt B, Cooper NR, May P, Rogers J (1994) Enhanced cytotoxicity of amyloid -peptide by a complement dependent mechanism. Neuroscience Letters 175: 99-102
Schumaker VN, Zavodszky P, Poon PH (1987) Activation of the first component of complement. Annual Review of Immunology 5: 21-42
Scolding NJ, Houston WA, Morgan BP, Campbell AK, Compston DA (1989) Reversible injury of cultured rat oligodendrocytes by complement. Immunology 67: 441-6
Shen Y, Lue L, Yang L, Roher A, Kuo Y, Stromeyer R, Goux WJ, Lee V, Johnson GV, Webster SD, Cooper NR, Bradt B, Rogers J (2001) Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neuroscience Letters 305: 165-8
Skribanek Z, Balaspiri L, Mak M (2001) Interaction between synthetic amyloid -peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. Journal of Mass Spectrometry 36: 1226-9
Spiegel K, Emmerling MR, Barnum SR (1998) Strategies for inhibition of complement activation int he treatment of neurodegenerative diseases. Neuroinflammation (szerkesztő Wood PL), Humana Press, Totowa, NJ. 129-76 oldal
Super M, Thiel S, Lu J, Levinsky RJ, Turner MW (1989) Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 2: 1236-9
Suzumura A, Mezitis SG, Gonatas NK, Silberberg DH (1987) MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon. Journal of Neuroimmunology 15: 263-78
Tacnet-Delorme P, Chevallier S, Arlaud GJ (2001) Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular region. Journal of Immunology 167: 6374-81
Takács I, Kerey G, Illés J, Rudolf P, Gere P, Czebe L, Neszmélyi E (1982) Process for production of organ extracts with high heparin content. US 4.315.923.
Tan F, Weerasinghe DK, Skidgel RA, Tamei H, Kaul RK, Roninson IB, Schilling JW, Erdős EG (1990) The deduced protein sequence of human carboxypeptidase N high molecular weight subunit reveals the presence of leucine-rich tandem repeats.
Journal of Biological Chemistry 265: 13-9
Tosi M, Duponchel C, Meo T, Julier C (1987) Complete cDNA sequence of human complement C1s and close physical linkage of the homologous genes C1s and C1r.
Biochemistry 26: 8516-24
Van den Berg RH, Faber-Krol MC, Sim RB, Daha MR (1998) The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and MCP-1 by human umbilical vein endothelial cells. Journal of Immunology 161: 6924-30
Vanguri P & Shin ML (1986) Activation of complement by myelin: Identification of C1 binding proteins of human myelin from the central nervous tissue.
Journal of Neurochemistry 46: 1535-41
Velazquez P, Cribbs DH, Poulos TL, Tenner AJ (1997) Aspartate residue 7 in amyloid -protein is critical for classical complement pathway activation.
Nature Medicine 3: 77-9
Walker DG, Kim SU, McGeer PL (1995) Complement and cytokine gene expression in cultured microglia derived from postmortem human brains.
Journal of Neuroscience Research 40: 478-93
Walker DG, Kim SU, McGeer PL (1998) Expression of complement C4 and C9 genes by human astrocytes. Brain Research 809: 31-8
Walport MJ (2001) Complement. New England Journal of Medicine 344: 1058-66
Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J (1997) Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer’s disease. Neurobiology of Aging 18: 415-21
Webster S, Tenner AJ, Poulos TL, Cribbs DH (1999) The mouse C1q A-chain sequence alters b-amyloid induced complement activation. Neurobiology of Aging 20: 297-304
Wisniewski KE, Dalton EJ, McLachlan DRC, Wen GY, Wisniewski HM (1985) Alzheimer’s disease in Down’s syndrome:clinico-pathologic studies. Neurology 17: 278-82
Wyss-Coray T & Mucke L (2002) Inflammation in neurodegenerative disease: a double-edged sword. Neuron 35: 419-32
Yang LB, Li R, Meri S, Rogers J, Shen Y (2000) Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer’s disease.
Journal of Neuroscience 20: 7505-9
Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Up-regulated production and activation of the complement system in Alzheimer’s disease brain.
American Journal of Pathology 154: 927-36
Ying SC, Gewurz AT, Jiang H, Gewurz H (1993) Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. Journal of Immunology 150: 169-76
Zalman LS, Wood LM, Müller-Eberhard HJ (1986) Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proceedings of National Academy of Sciences, USA 83: 6975-9
Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, Price JL (2005) Complement activation in very early Alzheimer disease.
Alzheimer’s Disease Associated Disorders 19: 55-66
Ziccardi RJ. (1985) Demonstration of the interaction of native C1 with monomeric immuno-globulins and C1 inhibitor. Journal of Immunology 134: 2559-63.
|
